JanOne Inc. added to the Russell Microcap® Index
Get Alerts JAN Hot Sheet
Join SI Premium – FREE
The Russell Microcap® Index was launched on
"Joining the Russell Microcap® Index is an important milestone for our company, especially at this juncture in our development and days after the closing of our acquisition of ALT 5 Sigma," said
About ALT 5 Sigma Inc.
Launched in 2018, ALT 5 is a fintech company that provides next generation blockchain-powered technologies to enable a migration to a new global financial paradigm. ALT 5, through its subsidiaries, offers two main platforms to its customers: "ALT 5 Pay" and "ALT 5 Prime."
ALT 5 Pay is a crypto-currency payment gateway that enables registered and approved global merchants to accept and make crypto-currency payments or to integrate the ALT 5 Pay payment platform into their application or operations using the plugin with WooCommerce and or ALT 5 Pay's checkout widgets and APIs. Merchants have the option to convert to fiat currency (US Dollars, Canadian Dollars, Euros, and British Pounds Sterling) automatically or to receive their payment in digital assets.
ALT 5 Prime is an electronic over-the-counter trading platform that enables registered and approved customers to buy and sell digital assets. Customers can purchase digital assets with fiat and, equally, can sell digital assets and receive fiat. ALT 5 Prime is available through a browser-based access mobile phone application named "ALT 5 Pro" that can be downloaded from the Apple App Store, from Google Play, through ALT 5 Prime's FIX API, as well as through Broadridge Financial Solutions' NYFIX gateway for approved customers.
About JanOne
JanOne is a unique Nasdaq-listed, multidisciplinary organization with a focus on healthcare and fintech. Through its biotech activities, JanOne is developing innovative, actionable solutions intended to help end the opioid crisis. JanOne is dedicated to funding resources toward innovation, technology, and education to find a key resolution to the national opioid epidemic, which is one of the deadliest and most widespread in the nation's history. Its drugs in the clinical trial pipeline have shown promise for their innovative targeting of the causes of pain as a strategic option for physicians averse to exposing patients to addictive opioids.
JanOne's ALT 5 subsidiary is a global fintech that provides next generation blockchain powered technologies for the trading, clearing, settlement, payment, and custodianship of digital instruments.
Please visit www.janone.com for additional information.
Forward Looking Statements
This press release contains statements that are forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to the statements that
Many factors could cause JanOne's actual results, performance or achievements to be materially different from any future results, performance or achievements described in this press release. Such factors could include, among others, those detailed in the Company's periodic reports filed with the Securities and Exchange Commission (the "SEC"). Should one or more of these risks or uncertainties materialize, or should the assumptions set out in the section entitled "Risk Factors" in JanOne's filings with the SEC underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this press release and JanOne does not intend, and does not assume any obligation, to update these forward-looking statements, except as required by law. JanOne cannot assure that such statements will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Individuals are cautioned that forward-looking statements are not guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein.
Media Contact Investor Relations
[email protected]
1-800-400-2247
View original content to download multimedia:https://www.prnewswire.com/news-releases/janone-inc-added-to-the-russell-microcap-index-302162152.html
SOURCE JanOne Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Hyperscale Data acquires 48.5 acres to expand Michigan campus
- OCI N.V. statement on NNS
- FDA approves Viridian's Lumvoa for thyroid eye disease
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
Definitive Agreement, Bitcoin, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share